Effect of orlistat on obese women with polycystic ovary syndrome
Abstract. Polycystic ovary syndrome (PCOS) is a common gynecological endocrine syndrome characterized by metabolic abnormality and reproductive dysfunction, including ovulation abnormality, hyperandrogenism and polycystic ovarian manifestations. Most PCOS patients are overweight or obese, particular...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Health
2018-12-01
|
Series: | Journal of Bio-X Research |
Online Access: | http://journals.lww.com/10.1097/JBR.0000000000000017 |
id |
doaj-e973c28580714605afbf87f3030ebe1f |
---|---|
record_format |
Article |
spelling |
doaj-e973c28580714605afbf87f3030ebe1f2020-11-25T03:42:46ZengWolters Kluwer HealthJournal of Bio-X Research2096-56722577-35852018-12-011312813110.1097/JBR.0000000000000017201812000-00005Effect of orlistat on obese women with polycystic ovary syndromeQi Jiang0Yuhua Shi1Center for Reproductive Medicine, Shandong University, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, the Key Laboratory for Reproductive Endocrinology of Ministry of Education, Shandong Provincial Clinical Medicine Research Center for Reproductive Health, Jinan, Shandong Province, China.Center for Reproductive Medicine, Shandong University, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, the Key Laboratory for Reproductive Endocrinology of Ministry of Education, Shandong Provincial Clinical Medicine Research Center for Reproductive Health, Jinan, Shandong Province, China.Abstract. Polycystic ovary syndrome (PCOS) is a common gynecological endocrine syndrome characterized by metabolic abnormality and reproductive dysfunction, including ovulation abnormality, hyperandrogenism and polycystic ovarian manifestations. Most PCOS patients are overweight or obese, particularly the central type. This aggravates the clinical manifestations of PCOS and ultimately increases the risk of infertility. Orlistat is the only weight loss drug approved by the US Food and Drug Administration. As a long-lasting gastrointestinal lipase inhibitor, orlistat can effectively reduce the absorption of lipid and increase lipid excretion, thereby achieving weight loss. In obese PCOS patients, orlistat can reduce weight, improve lipid metabolism and insulin resistance, improve sex hormone disorder, and have a positive effect on pregnancy outcome. This review summarizes the impact of orlistat treatment on metabolism and fertility in obese women with PCOS.http://journals.lww.com/10.1097/JBR.0000000000000017 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qi Jiang Yuhua Shi |
spellingShingle |
Qi Jiang Yuhua Shi Effect of orlistat on obese women with polycystic ovary syndrome Journal of Bio-X Research |
author_facet |
Qi Jiang Yuhua Shi |
author_sort |
Qi Jiang |
title |
Effect of orlistat on obese women with polycystic ovary syndrome |
title_short |
Effect of orlistat on obese women with polycystic ovary syndrome |
title_full |
Effect of orlistat on obese women with polycystic ovary syndrome |
title_fullStr |
Effect of orlistat on obese women with polycystic ovary syndrome |
title_full_unstemmed |
Effect of orlistat on obese women with polycystic ovary syndrome |
title_sort |
effect of orlistat on obese women with polycystic ovary syndrome |
publisher |
Wolters Kluwer Health |
series |
Journal of Bio-X Research |
issn |
2096-5672 2577-3585 |
publishDate |
2018-12-01 |
description |
Abstract. Polycystic ovary syndrome (PCOS) is a common gynecological endocrine syndrome characterized by metabolic abnormality and reproductive dysfunction, including ovulation abnormality, hyperandrogenism and polycystic ovarian manifestations. Most PCOS patients are overweight or obese, particularly the central type. This aggravates the clinical manifestations of PCOS and ultimately increases the risk of infertility. Orlistat is the only weight loss drug approved by the US Food and Drug Administration. As a long-lasting gastrointestinal lipase inhibitor, orlistat can effectively reduce the absorption of lipid and increase lipid excretion, thereby achieving weight loss. In obese PCOS patients, orlistat can reduce weight, improve lipid metabolism and insulin resistance, improve sex hormone disorder, and have a positive effect on pregnancy outcome. This review summarizes the impact of orlistat treatment on metabolism and fertility in obese women with PCOS. |
url |
http://journals.lww.com/10.1097/JBR.0000000000000017 |
work_keys_str_mv |
AT qijiang effectoforlistatonobesewomenwithpolycysticovarysyndrome AT yuhuashi effectoforlistatonobesewomenwithpolycysticovarysyndrome |
_version_ |
1724523743976357888 |